Interní Med. 2014; 16(1): 11-14

Absolute alcohol sclerotherapy under ultrasonographic control in the treatment of primary hyperparathyroidism

MUDr.Milan Halenka, Ph.D.1, doc.MUDr.David Karásek, Ph.D.1, doc.MUDr.Zdeněk Fryšák, CSc.1, doc.MUDr.Pavel Koranda, Ph.D.2
1 III. interní klinika &ndash, nefrologická, revmatologická, endokrinologická, FN a LF UP
2 Klinika nukleární medicíny, FN a LF UP v Olomouci

Primary hyperparathyroidism ranks third in frequency of endocrine diseases. More frequent testing ensues is why it is currently the

primary hyperparathyroidism revealed at a time when no clinical symptoms, the disease is asymptomatic form. The most common

cause is a solitary parathyroid adenoma. The basic method of treatment is surgery of course – parathyroidectomy. In some very specific

situations can be patients as an alternative to offer non-surgical intervention – absolute alcohol sclerotherapy under ultrasonographic

control. First of all, it can be recommended in severely ill patients, significantly less often after unsuccessful surgical exploration of the

neck or in the choice of the patient. The condition is good ultrasonography visualization od the adenoma and a physician erudite in the

implementation of this method. The method has been used since 1985 and therapeutic success is between 33–89 %.

Keywords: primary hyperparathyroidism, parathyroid adenoma, Percutaneous Ethanol Injection Therapy (PEIT)

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Halenka M, Karásek D, Fryšák Z, Koranda P. Absolute alcohol sclerotherapy under ultrasonographic control in the treatment of primary hyperparathyroidism. Interní Med. 2014;16(1):11-14.
Download citation

References

  1. Broulík P, Adámek S, Libánský P, Tvrdoň J. Diagnosis and treatment of primary hyperparathyroidism. Interní Med. 2007; 3: 130-132.
  2. Bilezikian JP, Khan AA, Potts JT Jr. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94: 335-339. Go to original source... Go to PubMed...
  3. Fraser WD. Hyperparathyroidism. Lancet. 2009; 374: 145-158. Go to original source... Go to PubMed...
  4. Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002; 87: 5353-5361. Go to original source... Go to PubMed...
  5. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94: 351-365. Go to original source... Go to PubMed...
  6. Garcia de la Torre N, Wass JA, Turner HE. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer. 2003; 10: 309-322. Go to original source... Go to PubMed...
  7. Karstrup S, Hegedüs L, Holm HH. Acute change in parathyroid function in primary hyperparathyroidism following ultrasonically guided ethanol injection into solitary parathyroid adenomas. Acta Endocrinol (Copenh). 1993; 129: 377-380. Go to original source... Go to PubMed...
  8. Solbiati L, Giangrande A, De Pra L, Bellotti E, Cant? P, Ravetto C. Percutaneous ethanol injection of parathyroid tumors under US guidance: treatment for secondary hyperparathyroidism. Radiology. 1985; 155: 607-610. Go to original source... Go to PubMed...
  9. Müller-Gärtner HW, Beil FU, Schneider C, Ringe JD, Greten H. Percutaneous transthyroidal instillation treatment of parathyroid adenoma with ethanol in primary hyperparathyroidism. Dtsch Med Wochenschr. 1987; 112: 1459-1461. Go to original source... Go to PubMed...
  10. Charboneau JW, Hay ID, van Heerden JA. Persistent primary hyperparathyroidism: successful ultrasound-guided percutaneous ethanol ablation of an occult adenoma. Mayo Clin Proc. 1988; 63: 913-917. Go to original source... Go to PubMed...
  11. Karstrup S, Transb?l I, Holm HH, Glenth?j A, Hegedüs L. Ultrasound-guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a prospective study. Br J Radiol. 1989; 62: 1037-1042. Go to original source... Go to PubMed...
  12. Karstrup S, Hegedüs L, Holm HH. Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study. Clin Endocrinol (Oxf). 1993; 38: 523-530. Go to original source... Go to PubMed...
  13. Verg?s BL, Cercueil JP, Jacob D, Vaillant G, Brun JM, Putelat R. Results of ultrasonically guided percutaneous ethanol injection into parathyroid adenomas in primary hyperparathyroidism. Acta Endocrinol (Copenh). 1993; 129: 381-387. Go to original source... Go to PubMed...
  14. Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, Thompson GB, Reading CC, Charboneau JW. Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery. 1998; 124: 1011-1019. Go to original source... Go to PubMed...
  15. Cercueil JP, Jacob D, Verges B, Holtzmann P, Lerais JM, Krause D. Percutaneous ethanol injection into parathyroid adenomas: mid- and long-term results. Eur Radiol. 1998; 8: 1565-1569. Go to original source... Go to PubMed...
  16. Stratigis S, Stylianou K, Mamalaki E, Perakis K, Vardaki E, Tzenakis N, Katsipi I, Papavasiliou S, Yarmenitis S, Kyriazis J, Daphnis E. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008; 69: 542-548. Go to original source... Go to PubMed...
  17. van Heerden JA, Grant CS. Surgical treatment of primary hyperparathyroidism: an institutional perspective. J Surg. 1991; 15: 688-692. Go to original source... Go to PubMed...
  18. Norman J, Politz D. Prospective study in 3,000 consecutive parathyroid operations demonstrates 18 objective factors that influence the decision for unilateral versus bilateral surgical approach. J Am Coll Surg. 2010; 211: 244-249. Go to original source... Go to PubMed...
  19. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002; 235: 665-670. Go to original source... Go to PubMed...
  20. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kakuta T, Onoda N, Koiwa F, Yumita S, Kurokawa K. Japanese Society for Parathyroid Intervention. Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant. 2003; 18(Suppl 3): 31-33. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.